The Impact of Anhedonia on the Disease Burden of Major Depressive Disorder in the Asia–Pacific Region: A Cross‐Sectional Real‐World Study
Neuropsychopharmacology Reports · 2025
DOI: 10.1002/npr2.70007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, 2025. Verfasst von Keira Herr und 9 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Asia Pacific, Singapore, Singapore. Hauptthemen laut MEDLINE: Major Depressive Disorder, Anhedonia, Quality of Life, Cost of Illness. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Asia Pacific, a division of Johnson & Johnson Pte Ltd.
Abstract (Originalsprache)
Aim
Anhedonia is a key symptom of major depressive disorder (MDD), however, its burden in patients with MDD is not well understood. We aimed to assess the impact of anhedonia on health‐related quality of life (HRQoL), health‐care resource utilization (HRU), and work productivity in subjects with MDD and anhedonia (MDD‐ANH) compared to subjects with MDD without ANH (MDD non‐ANH).
Methods
A cross‐sectional web‐based survey was conducted across six countries/territories. Adult participants were categorized as MDD‐ANH, MDD non‐ANH, and General Population based on self‐reported MDD diagnosis, Patient Health Questionnaire (PHQ‐9), and Snaith‐Hamilton Pleasure Scale (SHAPS). Multivariate/generalized linear regression modeling (GLMs) and mediation analysis were used to assess anhedonia's impact on HRQoL/function, HRU, and work productivity.
Results
Among 11 383 respondents, 20.1% were identified with MDD (MDD‐ANH: 12.7%; MDD non‐ANH: 7.3%) and 79.9% as General Population. Subjects with MDD‐ANH, compared with MDD non‐ANH demonstrated significantly worse or lower sexual functioning, HRQoL (RAND mental/physical component summary, health state utility (EuroQol) Index scores, all p < 0.001), and higher HRU (psychiatrist visits). Work productivity (higher absenteeism/overall work productivity or daily life impairment scores; all p < 0.05) was significantly worse in subjects with MDD‐ANH compared with MDD non‐ANH.
Conclusion
Anhedonia in patients with MDD had a significant negative impact on HRQoL, sexual functioning, work productivity, and HRU, emphasizing the need for focus on anhedonia management in MDD patients in the Asia–Pacific region.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Janssen Asia Pacific, Singapore, Singapore.
- School of Medicine, Deakin University, Melbourne, Australia.
- Department of Psychiatry, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.
- Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Psychiatry, College of Medicine, Haeundae Paik, Inje University, Busan, Republic of Korea.
- Paik Institute for Clinical Research, Inje University, Busan, Republic of Korea.
ORCID-Profile: Tadafumi Kato
Förderung
- Janssen Asia Pacific, a division of Johnson & Johnson Pte Ltd
Zitieren
APA
Herr, K., Berk, M., Huang, W. L., Kato, T., Lee, J. G., Ng, C. G., Wang, Z., Webb, T., Kasahara-Kiritani, M., & Vandervoort, L. (2025). The Impact of Anhedonia on the Disease Burden of Major Depressive Disorder in the Asia–Pacific Region: A Cross‐Sectional Real‐World Study. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.70007
Vancouver
Herr K, Berk M, Huang WL, Kato T, Lee JG, Ng CG, et al. The Impact of Anhedonia on the Disease Burden of Major Depressive Disorder in the Asia–Pacific Region: A Cross‐Sectional Real‐World Study. Neuropsychopharmacology Reports. 2025. doi:10.1002/npr2.70007
BibTeX
@article{Herr2025,
author = {Herr, Keira and Berk, Michael and Huang, Wei-Lieh and Kato, Tadafumi and Lee, Jung Goo and Ng, Chong Guan and Wang, Zhen and Webb, Thomas and Kasahara-Kiritani, Mami and Vandervoort, Lawrence},
title = {The Impact of Anhedonia on the Disease Burden of Major Depressive Disorder in the Asia–Pacific Region: A Cross‐Sectional Real‐World Study},
journal = {Neuropsychopharmacology Reports},
year = {2025},
doi = {10.1002/npr2.70007}
}
EUVIMED